What happened: On June 11, 2026, the Superior Court of Québec granted Health Canada a permanent injunction against Canlab Research, an online retailer of injectable peptides. Health Canada announced it on July 29, 2026.
What the injunction does
Per Health Canada’s announcement, Canlab Research and its representatives may not manufacture, test, distribute or sell unauthorized injectable peptides in Canada, may not help anyone else do so, and may not advertise or help others advertise them. That includes any website or social media platform accessible from a Canadian IP address.
Health Canada’s position is that injectable peptides are prescription drugs and need authorization before sale. It warns that unauthorized products can carry risks including hormonal imbalance, mood swings, blood sugar imbalance, liver or kidney damage, blood clots and tumour growth.
What the law firm commentary adds
Fasken’s life sciences bulletin of August 18, 2026 puts the case in context:
- Status depends on how it’s sold. Under the Food and Drugs Act a “drug” includes anything sold or represented for treating, preventing or modifying a disease or body function, so a peptide’s status depends on how it is represented as well as on the product. Fasken expects most peptides sold for human use to be treated as drugs needing authorization.
- Research-use labels are not a shield. A “for research purposes only” disclaimer does not decide the question. Fasken says Health Canada may weigh product format, website content, customer base, order patterns and the controls used to prevent personal use.
- Licensing may apply. Manufacturing, packaging, importing, testing, distributing or wholesaling drugs can require a Drug Establishment Licence.
- U.S. developments don’t carry over. Fasken notes that on July 23 and 24, 2026 an FDA advisory committee recommended wider access to six peptide substances through compounding pharmacies, but that does not change Health Canada’s position.
- More enforcement is possible. Health Canada has said it will keep monitoring compliance and may act again.
Why clinics should care
The case is about one retailer, not a clinic. But peptide products are showing up in wellness and aesthetic menus, and the regulator’s message is plain: the product has to be authorized, and the use has to be under a licensed professional’s care.
If your clinic offers or is asked about any peptide product:
- Check the DIN. Authorized drugs carry an eight-digit Drug Identification Number. Look it up in Health Canada’s Drug Product Database.
- Know your supplier. Keep supplier name, invoice and product details on file.
- Record the lot and expiry of every vial used on a client, and which client it went to. If a recall or safety notice arrives, you need to answer “who got this lot?” in minutes. Our guide to injectable lot and expiry tracking walks through the setup.
- Keep advertising in line. Prescription drug advertising to the public is tightly limited. See med spa advertising rules in Canada.
Where Zdrovia fits
Zdrovia’s inventory tracks lot numbers and expiry dates, uses first-expiry-first-out consumption, supports point-of-care dispensing and can quarantine a lot. That gives you the product-side audit trail this kind of enforcement environment rewards. It does not verify a DIN for you; that check is still yours.
This is general information, not legal advice. Talk to your regulator or counsel about any product you are unsure of.